PDF herunterladen
Semin Thromb Hemost 2002; 28(5): 431-438
DOI: 10.1055/s-2002-35283
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Hirudin in Heparin-Induced Thrombocytopenia

Norbert Lubenow, Andreas Greinacher
  • Ernst-Moritz-Arndt University, Greifswald, Germany
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
06. November 2002 (online)

    Lizenzen und Reprints

ABSTRACT

Heparin-induced thrombocytopenia (HIT), a serious side effect of heparin treatment, requires alternative anticoagulation in most affected patients. The recombinant hirudin (r-hirudin) lepirudin has been approved for this purpose after two prospective trials in laboratory-confirmed HIT patients. Other drugs available for this purpose are danaparoid sodium (a heparinoid) and argatroban, a synthetic direct thrombin inhibitor. In this article, recommendations for optimal use of r-hirudin in HIT are given, covering therapy in uncomplicated patients as well as in special situations such as heparin reexposure of HIT patients. Because lepirudin's half-life depends on renal function, it may vary between 1 and 200 hours, which requires individual dose adjustments. Lepirudin compares favorably with danaparoid, based on retrospective data. No direct comparisons of lepirudin with argatroban are available, but argatroban might offer advantages in patients with renal failure, because it is mainly eliminated hepatically. Major hemorrhage, the main risk of lepirudin treatment, occurring in about 15% of patients, makes close monitoring important. New monitoring tools, such as the ecarin clotting time (ECT), might further reduce bleeding risks. Antihirudin antibodies, which can alter the pharmacokinetics as well as the pharmacodynamics of hirudin, can also be countered by close monitoring and appropriate dose adjustments. Whereas hirudins have not yet managed to gain importance in non-HIT indications such as unstable coronary syndromes, they have a major role to play in the treatment of HIT. The choice between the available drugs for HIT, namely lepirudin, danaparoid, and argatroban, has to be made according to the clinical presentation of the patient.

KEYWORDS

Heparin-induced thrombocytopenia - HIT - lepirudin - hirudin - danaparoid - argatroban

REFERENCES

  • 1 Warkentin T E, Levine M N, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med . 1995;  332 1330-1335
    CrossrefPubMedGoogle Scholar
  • 2 Warkentin T E, Chong B H, Greinacher A. Heparin-induced thrombocytopenia: towards consensus.  Thromb Haemost . 1998;  79 1-7
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 3 Amiral J, Bridey F, Wolf M. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases.  Thromb Haemost . 1995;  73 21-28
    PubMedGoogle Scholar
  • 4 Amiral J, Marfaing-Koka A, Wolf M. Presence of autoantibodies to interleucin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia.  Blood . 1996;  88 410-416
    PubMedGoogle Scholar
  • 5 Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific.  Thromb Haemost . 1992;  67 545-549
    PubMedGoogle Scholar
  • 6 Cines D B, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia.  N Engl J Med . 1987;  316 581-589
    CrossrefPubMedGoogle Scholar
  • 7 Visentin G P, Ford S E, Scott J P, Aster R H. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.  J Clin Invest . 1994;  93 81-88
    CrossrefPubMedGoogle Scholar
  • 8 Greinacher A, Poetzsch B, Amiral J. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen.  Thromb Haemost . 1994;  71 247-251
    CrossrefPubMedGoogle Scholar
  • 9 Chong B H, Fawaz I, Chestermann C N, Berndt M C. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets.  Br J Haematol . 1989;  73 235-240
    PubMedGoogle Scholar
  • 10 Kelton J G, Sheridan D, Santos A. Heparin-induced thrombocytopenia: laboratory studies.  Blood . 1988;  72 925-930
    PubMedGoogle Scholar
  • 11 Chong B H, Murray B, Berndt M C. Plasma P-selectin is increased in thrombotic consumptive platelet disorders.  Blood . 1994;  83 1535-1541
    CrossrefPubMedGoogle Scholar
  • 12 Warkentin T E, Hayward C P, Boshkov L K. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.  Blood . 1994;  84 3691-3699
    CrossrefPubMedGoogle Scholar
  • 13 Arepally G M, Mayer I M. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8.  Blood . 2001;  98 1252-1254
    CrossrefPubMedGoogle Scholar
  • 14 Pouplard C, Iochmann S, Renard B. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia.  Blood . 2001;  97 3300-3302
    CrossrefPubMedGoogle Scholar
  • 15 Warkentin T E. Limitations of conventional treatment options for heparin-induced thrombocytopenia.  Semin Hematol . 1998;  35 17-25
    PubMedGoogle Scholar
  • 16 Warkentin T E, Kelton J E. A 14-year study of heparin-induced thrombocytopenia.  Am J Med . 1996;  101 502-507
    CrossrefPubMedGoogle Scholar
  • 17 Wallis D E, Workman D L, Lewis B E. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia.  Am J Med . 1999;  106 629-635
    CrossrefPubMedGoogle Scholar
  • 18 Warkentin T E, Elavathil L J, Hayward C P. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia.  Ann Intern Med . 1997;  127 804-812
    CrossrefPubMedGoogle Scholar
  • 19 Ganzer D, Gutezeit A, Mayer G. Potential risks in drug prevention of thrombosis-low-molecular-weight heparin versus standard heparin.  Z Orthop Ihre Grenzgeb . 1999;  137 457-461
    PubMedGoogle Scholar
  • 20 Alban S, Greinacher A. Role of sulfated polysaccharides in the pathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 2nd ed New York: Marcel Dekker 2001: 167-187
    Google Scholar
  • 21 Mayo D J, Cullinane A M, Merryman P K, Horne III K M. Serologic evidence of heparin sensitization in cancer patients receiving heparin flushes of venous access devices.  Support Care Cancer . 1999;  7 425-427
    PubMedGoogle Scholar
  • 22 Lee D H, Warkentin T E. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 2nd ed New York: Marcel Dekker 2001: 87-121
    Google Scholar
  • 23 Greinacher A, Warkentin T E. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 2nd ed New York: Marcel Dekker 2001: 291-322
    Google Scholar
  • 24 Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.  Thromb Haemost . 2001;  85 950-957
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 25 Greinacher A, Völpel H, Janssens U. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia: a prospective study.  Circulation . 1999;  99 73-80
    CrossrefPubMedGoogle Scholar
  • 26 Greinacher A, Janssens U, Berg G. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia.  Circulation . 1999;  100 587-593
    CrossrefPubMedGoogle Scholar
  • 27 Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia.  Thromb Haemost . 1991;  66 734-736
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 28 Eichler P, Budde U, Haas S. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA.  Thromb Haemost . 1999;  81 625-629
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 29 Lewis B E, Wallis D E, Berkowitz S D, for the ARG-911 Study investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.  Circulation . 2001;  103 1838-1843
    CrossrefPubMedGoogle Scholar
  • 30 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.  Blood . 2000;  96 846-851
    CrossrefPubMedGoogle Scholar
  • 31 Huhle G, Hoffmann U, Hoffmann I. A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study.  Thromb Res . 2000;  99 325-334
    CrossrefPubMedGoogle Scholar
  • 32 Warkentin T E, Kelton J G. Temporal aspects of heparin-induced thrombocytopenia.  N Engl J Med . 2001;  344 1286-1292
    CrossrefPubMedGoogle Scholar
  • 33 Lubenow N, Kempf R, Eichner A. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or exposure to heparin.  Chest . 2002;  122 37-42
    CrossrefPubMedGoogle Scholar
  • 34 Pötzsch B, Madlener K. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 2nd ed New York: Marcel Dekker 2001: 429-444
    Google Scholar
  • 35 Pötzsch B, Klovekorn W P, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia (Letter).  N Engl J Med . 2000;  343 515
    CrossrefPubMedGoogle Scholar
  • 36 Selleng S, Lubenow N, Wollert H-G, Müllejans B, Greinacher A. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin.  Ann Thorac Surg . 2000;  71 1041-1042
    PubMedGoogle Scholar
  • 37 van Wyk V, Badenhorst P N, Luus H G, Kotzé H F. A comparison between the use of recombinant hirudin and heparin during hemodialysis.  Kidney Int . 1995;  48 1338-1343
    PubMedGoogle Scholar
  • 38 Vanholder R, Camez A, Veys N. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.  Thromb Haemost . 1997;  77 650-655
    PubMedGoogle Scholar
  • 39 Hempel S, Lubenow N, Greinacher A. Nierenersatztherapie unter r-Hirudin (Refludan) bei Heparin-induzierter Thrombozytopenie Typ II (Abst).  Infusionsther Transfusionsmed . 1998;  25 5/7
    PubMedGoogle Scholar
  • 40 Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: a randomized trial. Lancet 1999 353: 429-438
    Google Scholar
  • 41 Hafner G, Rupprecht H J, Luz M. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris [see comments].  Eur Heart J . 1996;  17 1207-1215
    PubMedGoogle Scholar
  • 42 Rupprecht H J, Terres W, Ozbek C. Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina.  J Am Coll Cardiol . 1995;  26 1637-1642
    CrossrefPubMedGoogle Scholar
  • 43 Neuhaus K L, Molhoek G P, Zeymer U. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial.  J Am Coll Cardiol . 1999;  34 966-973
    CrossrefPubMedGoogle Scholar
  • 44 Antman E M. Hirudin in acute myocardial infarction. Thrombolysis and thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial [see comments].  Circulation . 1996;  94 911-921
    CrossrefPubMedGoogle Scholar
  • 45 Schiffmann H, Unterhalt M, Harms K. Successful treatment of heparin-induced thrombocytopenia (HIT) type II in childhood with recombinant hirudin.  Monatsschr Kinderheilkd . 1997;  145 606-612
    CrossrefPubMedGoogle Scholar
  • 46 Eriksson B I, Ekman S, Lindbratt S. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.  J Bone Joint Surg Am . 1997;  79 326-333
    PubMedGoogle Scholar
  • 47 Eriksson B I, Wille-Jörgensen P, Kälebo P. A comparison of recombinant hirudin with a low-molecular weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med . 1997;  337 1329-3135
    CrossrefPubMedGoogle Scholar